EBS
Emergent BioSolutions Inc. · Healthcare · Market cap $318.4M
Insiders sold $543K net in the last 90 days ·5 sellers, 0 buyers· 3 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Jul 2, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Jul 2, 2026
Williams Paul Anthony
Emergent BioSolutions Inc. (EBS) has 45 SEC Form 4 filings (59 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 2, 2026.
Inside the rolling window, 7 insiders at Emergent BioSolutions Inc. reported no open-market purchases and 10 open-market sales totaling $1.4M. Insiders have net sold $577K over the trailing 6 months. The most recent open-market filing is a sale of 3,000 shares by SVP, Products Business Williams Paul Anthony, dated Jul 1, 2026, worth $25K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Joseph C. Papa Jr.
- Employees:900
- HQ:Gaithersburg, MD, US
- IPO:2006-11-15
| Source | |||||||
|---|---|---|---|---|---|---|---|
Williams Paul AnthonyFirst in 3 months | SVP, Products Business | Sale | 3,000 | $25K | Jul 2 | -25.0% | SEC ↗ |
Dayal Sujata TyagiFirst in 6 months | Director | Sale | 13,761 | $116K | May 4 | -27.3% | SEC ↗ |
DeGolyer Donald WFirst in 6 months | Director | Sale | 15,481 | $130K | May 4 | -27.3% | SEC ↗ |
Zoon Kathryn CFirst filing | Director | Sale | 17,202 | $144K | May 4 | -27.3% | SEC ↗ |
Katkin KeithFirst filing | Director | Sale | 15,481 | $128K | May 4 | -27.3% | SEC ↗ |
Williams Paul AnthonyFirst filing | SVP, Products Business | Sale | 4,000 | $34K | Apr 3 | -23.3% | SEC ↗ |
Richard RonaldFirst filing | Director | Sale | 21,984 | $263K | Dec 9 | -46.6% | SEC ↗ |
DeGolyer Donald WFirst filing | Director | Sale | 17,801 | $188K | Nov 12 | — | SEC ↗ |
Dayal Sujata TyagiFirst filing | Director | Sale | 8,552 | $86K | Nov 10 | — | SEC ↗ |
Glessner ColeenFirst filing | EVP, Quality & Ethics, and CPL | Sale | 30,608 | $306K | Oct 16 | — | SEC ↗ |
Congress trading EBS 13 all-time
- DRep. Stephen CohenOther$1,001 - $15,0002024-12-11
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-11-05
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002021-10-18
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-09-15
- DRep. Josh S. GottheimerOther$1,001 - $15,0002021-02-23
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002020-11-24
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does EBS have?
Emergent BioSolutions Inc. (EBS) has 45 SEC Form 4 filings (59 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Jul 2, 2026.
When was the most recent SEC Form 4 filing for EBS?
The most recent Form 4 filing for EBS on Tracefour is dated Jul 2, 2026.
What is the net insider flow at EBS over the last 6 months?
Over the trailing 180 days, insiders at EBS have net sold $577K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at EBS in the current window?
Inside the rolling window, insiders at EBS bought $0 and sold $1.4M based on SEC Form 4 filings.
Can I get alerts for EBS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Emergent BioSolutions Inc. (EBS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Emergent BioSolutions Inc. is in the Healthcare sector.